July 1, 2021

Arnd Christ Chief Financial Officer Immatics Biotechnologies GmbH Machtlfinger Str. 11 81379 Munich Germany

Re: Immatics N.V. Form 20-F for the

fiscal year ended December 31, 2020

Filed March 30,

2021

File No. 001-39363

Dear Mr. Christ:

We have limited our review of your filing to the financial statements and related $% \left(1\right) =\left(1\right) +\left(1\right) +$

with information so we may better understand your disclosure.

Please respond to this comment within ten business days by providing the requested

information or advise us as soon as possible when you will respond. If you do not believe our

comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to this comment, we may have additional comments.

Form 20-F for the fiscal year ended December 31, 2020

Item 5. Operating and Financial Review and Prospects Results of Operations Research and Development Expenses, page 121

1. Please provide us an analysis of external research and development expenses incurred for each year presented for ACT expenses and TCR Biospecifics separately. Please provide us with proposed disclosure to be included in future periodic reports which separately quantifies your research and development expense by project. If you do not track your research and development costs by project, disclose that fact as well as why you do not maintain and evaluate research and development costs by project.

 $\,$ $\,$ In closing, we remind you that the company and its management are responsible for the

accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or

Arnd Christ

Immatics Biotechnologies GmbH

July 1, 2021

Page 2

absence of action by the staff.

You may contact Vanessa Robertson at 202-551-3649 or Kevin Vaughn at 202-551-3494 with any questions.

FirstName LastNameArnd Christ Comapany NameImmatics Biotechnologies GmbH Sincerely,

Division of Corporation